NL-OMON51513
Recruiting
Not Applicable
International multicenter observational study to determine the diagnostic sensitivity of plasma metanephrines and urinary catecholamines and metabolites compared to standard evaluation procedures in children with high risk neuroblastoma - Metanephrines
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Centre Hospitalier Universitaire Vaudois-CHUV
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with confirmed high risk neuroblastoma (clinical and/or biological)
- •Patients treated within or according to SIOPEN HR\-NBL\-2 clinical trial
- •Age \< 18 years at inclusion, male or female
- •Ethic committee approval for each participating site
- •Informed consent signed by the legal representatives and/or by the child
- •according to local regulations
Exclusion Criteria
- •Renal insufficiency (creatinine clearance according to Schwartz formula \<
- •60ml/min/m2\)
- •Absence of histological confirmation of high risk neuroblastoma
- •Lack of consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
International Multi-Center Observational Study of Lung-protective Ventilation in Asian ICUsDiseases of th respiratory systemKCT0004270Asan Medical Center1,000
Not yet recruiting
Not Applicable
A study international multi center study to find out the current practices using in patient admitted in intensive care unit while giving breathing with the help of artificial breathing machine in intensive care units across all Asia.Health Condition 1: J969- Respiratory failure, unspecifiedCTRI/2019/07/020215Tata Memorial Hospital
Active, not recruiting
Not Applicable
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeMedDRA version: 14.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2009-013884-21-DEEnceladus Pharmaceuticals BV90
Active, not recruiting
Phase 1
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)EUCTR2009-013884-21-BEEnceladus Pharmaceuticals BV90
Active, not recruiting
Not Applicable
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeMedDRA version: 14.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2009-013884-21-PLEnceladus Pharmaceuticals BV90